Literature DB >> 27336683

Development of PEGylated Cysteine-Modified Lysine Dendrimers with Multiple Reduced Thiols To Prevent Hepatic Ischemia/Reperfusion Injury.

Hidemasa Katsumi1, Makiya Nishikawa2, Rikiya Hirosaki1, Tatsuya Okuda3,4, Shigeru Kawakami3,5, Fumiyoshi Yamashita3, Mitsuru Hashida3, Toshiyasu Sakane1, Akira Yamamoto1.   

Abstract

To inhibit hepatic ischemia/reperfusion injury, we developed polyethylene glycol (PEG) conjugated (PEGylated) cysteine-modified lysine dendrimers with multiple reduced thiols, which function as scavengers of reactive oxygen species (ROS). Second, third, and fourth generation (K2, K3, and K4) highly branched amino acid spherical lysine dendrimers were synthesized, and cysteine (C) was conjugated to the outer layer of these lysine dendrimers to obtain K2C, K3C, and K4C dendrimers. Subsequently, PEG was reacted with the C residues of the dendrimers to obtain PEGylated dendrimers with multiple reduced thiols (K2C-PEG, K3C-PEG, and K4C-PEG). Radiolabeled K4C-PEG ((111)In-K4C-PEG) exhibited prolonged retention in the plasma, whereas (111)In-K2C-PEG and (111)In-K3C-PEG rapidly disappeared from the plasma. K4C-PEG significantly prevented the elevation of plasma alanine aminotransferase (ALT) activity, an index of hepatocyte injury, in a mouse model of hepatic ischemia/reperfusion injury. In contrast, K2C-PEG, K3C-PEG, l-cysteine, and glutathione, the latter two of which are classical reduced thiols, hardly affected the plasma ALT activity. These findings indicate that K4C-PEG with prolonged circulation time is a promising compound to inhibit hepatic ischemia/reperfusion injury.

Entities:  

Keywords:  PEGylation; cysteine; dendrimer; drug delivery; hepatic ischemia/reperfusion injury; reactive oxygen species; thiol

Mesh:

Substances:

Year:  2016        PMID: 27336683     DOI: 10.1021/acs.molpharmaceut.6b00557

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  4 in total

1.  l-Serine-modified polyamidoamine dendrimer as a highly potent renal targeting drug carrier.

Authors:  Satoru Matsuura; Hidemasa Katsumi; Hiroe Suzuki; Natsuko Hirai; Hidetaka Hayashi; Kazuhiro Koshino; Takahiro Higuchi; Yusuke Yagi; Hiroyuki Kimura; Toshiyasu Sakane; Akira Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-24       Impact factor: 11.205

Review 2.  Drug delivery nanosystems targeted to hepatic ischemia and reperfusion injury.

Authors:  Margarida Ferreira-Silva; Catarina Faria-Silva; Pedro Viana Baptista; Eduarda Fernandes; Alexandra Ramos Fernandes; Maria Luísa Corvo
Journal:  Drug Deliv Transl Res       Date:  2021-03-03       Impact factor: 4.617

Review 3.  Pre-conditions for eliminating mitochondrial dysfunction and maintaining liver function after hepatic ischaemia reperfusion.

Authors:  Chenxia Hu; Lanjuan Li
Journal:  J Cell Mol Med       Date:  2017-03-16       Impact factor: 5.310

4.  l-Cysteine and l-Serine Modified Dendrimer with Multiple Reduced Thiols as a Kidney-Targeting Reactive Oxygen Species Scavenger to Prevent Renal Ischemia/Reperfusion Injury.

Authors:  Satoru Matsuura; Hidemasa Katsumi; Hiroe Suzuki; Natsuko Hirai; Rie Takashima; Masaki Morishita; Toshiyasu Sakane; Akira Yamamoto
Journal:  Pharmaceutics       Date:  2018-12-01       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.